Support Article

Quantifying Brain Clearance Through BAT Testing and BATChecks

This white paper outlines a practical model for tracking brain-clearance biology over time using paired BAT Testing and BATCheck workflows. The central idea is simple: use direct plasma biomarker measurement for Beta-Amyloid and Tau, then interpret those results inside a broader longitudinal check-in model.

What the Paper Proposes

The paper proposes a non-invasive, real-world monitoring framework that moves beyond one-time testing and toward repeatable trend tracking. BAT Testing is used to measure molecular clearance balance, while BATCheck adds upstream context from metabolic, inflammatory, and related markers that may influence that balance.

Together, the two are presented as a way to quantify clearance rhythm as an ongoing biological pattern rather than a single event.

Core Measurement Model

The framework is built around plasma Beta-Amyloid and Tau biomarkers, especially the Aβ42/40 and pTau signal family, then organized into BAT Levels and BATScore-style trend interpretation over time.

The paper emphasizes repeated follow-up because clearance patterns are more informative as a sequence than as an isolated result.

How BAT Testing and BATCheck Connect

• BAT Testing provides the direct plasma biomarker measurement.
• BATCheck provides a structured review layer and follow-up model.
• BATScore provides a simplified summary signal to help compare changes over time.

This combination is the main operational contribution described in the paper.

Public-Health Context in the Paper

The paper places this framework in a prevention-oriented public-health context and references alignment with broader priorities discussed by WHO, NIH, and CDC around earlier monitoring and risk reduction planning.

Its practical goal is scale: make biologic monitoring feasible in everyday settings rather than limiting access to specialty research pathways.

Limits the Paper States Clearly

• It is presented as a feasibility and implementation framework, not a diagnostic test claim.
• The observations include early de-identified registry data and are stated as not yet peer-reviewed.
• The model is intended for longitudinal monitoring and provider-guided interpretation.

Research Reference

Parent Article

Related Articles

Recommended Direction